Related Experiment Video

Updated: May 9, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

Reduced expression of steroid sulfatase in primary colorectal cancer

Agnieszka Anna Rawłuszko1, Monica Antoniucci, Karolina Horbacka

  • 1Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, Poznań, Poland.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|August 7, 2013
PubMed

Insights

Steroid sulfatase (STS) expression decreases in colorectal cancer (CRC) development. Sodium butyrate (NaBu) may increase STS levels in CRC cells, offering potential therapeutic insights for this estrogen-dependent malignancy.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Colorectal cancer (CRC) is an estrogen-dependent malignancy.
  • Intratissue estrogen levels are regulated by steroid sulfatase (STS).
  • STS expression changes during CRC development remain largely uncharacterized.

Purpose of the Study:

  • To investigate STS mRNA levels in primary colorectal adenocarcinoma.
  • To explore the effect of sodium butyrate (NaBu) on STS expression in CRC cells.

Main Methods:

  • Analysis of STS mRNA levels in 90 primary colon adenocarcinoma tissues and adjacent normal mucosa.
  • Quantitative assessment of STS transcript levels via RT-qPCR.
  • Treatment of DLD-1 and HCT116 CRC cell lines with sodium butyrate (NaBu).

Main Results:

  • A statistically significant decrease in STS transcript levels was observed in CRC tissues compared to normal mucosa (P=0.0453).
  • Sodium butyrate (NaBu) significantly upregulated STS transcript levels in both DLD-1 and HCT116 CRC cell lines.
  • STS expression may be reduced during colorectal carcinogenesis.

Conclusions:

  • STS expression is decreased in colorectal adenocarcinoma.
  • Sodium butyrate (NaBu) demonstrates potential to increase STS expression in CRC cells.
  • Findings suggest a role for STS modulation in CRC development and potential therapeutic strategies.
Keywords:
ButyrateColorectal cancerSteroid sulfatase

More Related Videos

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells06:38

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

Published on: January 22, 2021

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.